abiraterone
Selected indexed studies
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. (Lancet, 2022) [PMID:35405085]
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. (Lancet Oncol, 2023) [PMID:37714168]
- Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. (NEJM Evid, 2022) [PMID:38319800]
_Worker-drafted node — pending editorial review._
Connections
abiraterone is a side effect of
Sources
- [Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)]. (2019) pubmed
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. (2022) pubmed
- Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. (2023) pubmed
- Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2022) pubmed
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. (2026) pubmed
- AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. (2014) pubmed
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. (2021) pubmed
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. (2015) pubmed
- Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study. (2025) pubmed
- Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. (2021) pubmed